Elanco Q1 2022 Earnings Report
Key Takeaways
Elanco Animal Health reported a decrease of 1% in revenue, totaling $1,225 million for Q1 2022, but an increase of 2% excluding the impact of foreign exchange rates. Adjusted EBITDA was $339 million, a 1% decrease compared to Q1 2021. The company is adjusting its full year guidance to account for the strengthening U.S. dollar.
Revenue was $1,225 million, a decrease of 1% on a reported basis, or an increase of 2% excluding the unfavorable impact of foreign exchange rates.
Pet Health revenue was $639 million, a decrease of 1% on a reported basis or an increase of 2% excluding the unfavorable impact from foreign exchange rates, with a 2% increase from price.
Farm Animal revenue was $569 million, a decrease of 2% on a reported basis or an increase of 1% excluding the unfavorable impact from foreign exchange rates, with a 1% increase from price.
Adjusted EBITDA was $339 million, a decrease of 1% compared to the first quarter of 2021.
Elanco
Elanco
Forward Guidance
Elanco is updating financial guidance for the full year 2022 and providing financial guidance for the second quarter of 2022.
Positive Outlook
- The implied guidance for the second half of 2022 includes an acceleration of revenue and profitability growth.
- The company’s initial guidance for full year 2022 in February included an expected second half acceleration of revenue growth from price increases, the improvement of year over year unfavorable comparisons across many parts of the business, including contract manufacturing, and the increasing contribution from innovation.
- The company’s updated guidance for full year 2022 now includes expected benefit from incremental price improvement and sales phasing in China from the second quarter of 2022 to the second half of 2022 from expected easing of COVID-19 restrictions.
- For the full year 2022, the company now anticipates revenue between $4,700 million and $4,755 million.
- For the second quarter of 2022, the company anticipates revenue between $1,160 million and $1,200 million.
Challenges Ahead
- The company has updated its guidance for reported net income, adjusted EBITDA, reported EPS and adjusted EPS to reflect the impact of the strengthening U.S. dollar.
- The company now anticipates revenue between $4,700 million and $4,755 million, including a headwind of approximately $140 million from the unfavorable impact of foreign exchange rates compared to 2021.
- The expected 4% revenue decline at constant currency for the second quarter 2022 is primarily driven by emerging macro conditions including the situations in China, Ukraine and Russia, as well as stock-outs of certain U.S. pet health products and a partial shift of aqua product demand into the first quarter from the second quarter as a result of strong underlying salmon market prices.
- Importantly, the company expects headwinds from the war in Ukraine to continue the rest of this year.
- The financial guidance reflects foreign exchange rates as of the beginning of May.